Education
About Us
Working with TipRanks
Follow Us
Intelligent Bio Solutions Inc. (INBS)
NASDAQ:INBS
INBS Stock Chart & Stats
$1.03
-$0.03(-2.02%)
At close: 4:00 PM EST
$1.03
-$0.03(-2.02%)
Day’s Range― - ―
52-Week Range$3.70 - $25.00
Previous CloseN/A
Volume32.28K
Average Volume (3M)149.43K
Market Cap
$6.58M
Enterprise Value$1.62M
Total Cash (Recent Filing)$740.37K
Total Debt (Recent Filing)$3.45M
Price to Earnings (P/E)―
Beta1.68
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.82
Shares Outstanding1,603,783
10 Day Avg. Volume198,943
30 Day Avg. Volume149,426
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)3.03
Price to Sales (P/S)2.97
P/FCF Ratio-0.92
Enterprise Value/Market Cap0.25
Enterprise Value/Revenue0.45
Enterprise Value/Gross Profit1.51
Enterprise Value/Ebitda-0.16
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Manufacturing Scale & Margin ImprovementA strategic manufacturing partnership that multiplies capacity ~4x and targets >40% production cost savings is a durable structural improvement. It materially lowers per-unit costs, supports faster fulfillment, reduces supply-chain risk, and underpin long-term gross margin expansion as volume scales into new markets.
Regulatory Pathway To U.S. MarketA clinical program aimed at an FDA 510(k) submission represents a structural shift from "Forensic Use Only" toward cleared U.S. commercial markets. Successful clearance would expand total addressable market, enable broader clinical and workplace use, and create a durable revenue runway vs. reliance on limited niches.
Top-line Momentum With Healthy Product EconomicsImproving revenue and a solid ~46% gross margin indicate core product economics that can scale profitably as volumes rise. Low leverage (debt/equity ~0.17) provides balance-sheet flexibility to fund operations or absorb variability, making growth initiatives and margin gains more sustainable long term.
Bears Say
High Cash Burn & Negative Free Cash FlowSustained ~-$9M operating and free cash flow over the trailing year signals structural cash consumption that must be addressed. Persistent burn forces management to prioritize fundraising or deep cost cuts, constraining strategic flexibility and increasing execution risk until operations generate positive cash flow.
Severe Net Losses And Negative MarginsExtremely negative net margins (~-315%) reflect a cost structure far outstripping revenues. Even with improving revenue and gross margin, fixed and operating expenses keep the company deeply unprofitable, implying a lengthy path to breakeven and persistent pressure on returns and investor tolerance.
Ongoing External Financing And Dilution RiskA recent $10M at-the-market private placement with pre-funded warrants and exerciseable warrants highlights reliance on capital markets to fund operations. Continued external funding needs increase dilution risk, create potential share overhang from warrants, and signal insufficient internal cash generation today.
Intelligent Bio Solutions News
INBS FAQ
What was Intelligent Bio Solutions Inc.’s price range in the past 12 months?
Intelligent Bio Solutions Inc. lowest stock price was $3.70 and its highest was $25.00 in the past 12 months.
What is Intelligent Bio Solutions Inc.’s market cap?
Intelligent Bio Solutions Inc.’s market cap is $6.58M.
When is Intelligent Bio Solutions Inc.’s upcoming earnings report date?
Intelligent Bio Solutions Inc.’s upcoming earnings report date is May 13, 2026 which is in 69 days.
How were Intelligent Bio Solutions Inc.’s earnings last quarter?
Intelligent Bio Solutions Inc. released its earnings results on Feb 12, 2026. The company reported -$2.82 earnings per share for the quarter, missing the consensus estimate of N/A by -$2.82.
Is Intelligent Bio Solutions Inc. overvalued?
According to Wall Street analysts Intelligent Bio Solutions Inc.’s price is currently Overvalued.
Does Intelligent Bio Solutions Inc. pay dividends?
Intelligent Bio Solutions Inc. does not currently pay dividends.
What is Intelligent Bio Solutions Inc.’s EPS estimate?
Intelligent Bio Solutions Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Intelligent Bio Solutions Inc. have?
Intelligent Bio Solutions Inc. has 1,603,783 shares outstanding.
What happened to Intelligent Bio Solutions Inc.’s price movement after its last earnings report?
Intelligent Bio Solutions Inc. reported an EPS of -$2.82 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.667%.
Which hedge fund is a major shareholder of Intelligent Bio Solutions Inc.?
Currently, no hedge funds are holding shares in INBS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Technical Analysis
―
iSpecimen
―
BioNexus Gene Lab Corp
―
Mainz Biomed B.V.
―
bioAffinity Technologies, Inc.
―
Ownership Overview
―
Insiders
4.78% Mutual Funds
0.02% Other Institutional Investors
94.73% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---